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Summary 
 
A total of 1,470 pigs were used to study a 
commercial sow herd with a history of Porcine 
Circovirus Disease (PCVD). The objective 
was to evaluate the effect of two commercially 
available Porcine Circovirus Type 2 (PCV2) 
vaccines on growth and mortality rates. The 
first vaccine was administered one week after 
weaning (1-dose) while the second was ad-
ministered at weaning and repeated three 
weeks later (2-dose). A third group of unvac-
cinated pigs served as a control group. Pigs 
were individually weighed at weaning (d 0), d 
113, 143, and just prior to market. On d 113, 
pigs on the 2-dose treatment were heavier 
(P<0.05) than the control group, and the 1-
dose treatment pigs were intermediate. At d 
143, just prior to when the first pigs were 
marketed, both the 1-dose and the 2-dose pigs 
were heavier than the control pigs by 7.6 and 
10.2 lb (P<0.05), respectively, and there were 
no significant differences in weights between 
the two vaccinated groups. However, differ-
ences in weights between the vaccinated and 
the control pigs were smaller at off-test com-
pared to differences at d 143 due to a wider 
variability in on-test days as a result of multi-
ple marketing days prior to end of the trial. 
Although there were no significant differences 
between the two vaccinated groups, ADG was 
greater (P<0.05) in all vaccinated pigs com-
pared to non-vaccinated control pigs from d 0 
to d 113, d 143, and at off-test. From d 113 to 
143 and until the day they were taken off test, 
there were no differences in ADG, regardless 
of treatment. This suggests that the increase in 
growth rate in vaccinated pigs occurred during 
the period d 0 to 113. Barrows consistently 
exhibited greater ADG and heavier weights 
(P<0.05) than gilts throughout the trial. No 
significant differences in mortality rate be-
tween treatments were observed but both vac-
cinated groups had mortality rates that were 
3% lower than the non-vaccinated control 
pigs. Based on these results, both commercial 
vaccines were effective in mitigating the ef-
fects of PCV2 virus and improving the growth 
performance of pigs in a PCV2 positive herd. 
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Introduction 
 
 Porcine Circovirus Diseases (PCVD) is 
considered a disease of major economic im-
portance because of its ability to cause high 
death loss and poor growth performance. The 
disease is caused by Porcine Circovirus Type 
2 (PCV2) and the condition is usually non-
responsive to antibiotic treatment due to the 
viral cause. Clinical signs of the disease in-
clude poor body condition with varying de-
grees of muscle wasting, labored breathing, 
and enlarged lymph nodes. Death loss can be 
as high as 40% in severely affected herds. The 
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PCV2 virus is very stable and resistant to in-
activation. Preventing or minimizing the 
chances of infection requires exceptionally 
good husbandry practices. Although research-
ers have confirmed PCV2 as the main infec-
tious agent to trigger the disease, PCVD may 
require other factors or agents for clinical 
signs and lesions to appear. Positive responses 
and initial field results with the use of recently 
developed vaccines have further confirmed the 
major role PCV2 plays in the development of 
the disease. These results have been very 
promising; however, most of these were re-
ported in terms of mortality reduction and 
very little study has been done with the vac-
cine in terms of growth performance. There-
fore, the objective of this trial was to compare 
the effects of two commercially available 
PCV2 vaccines (1- or 2-dose) on growth rate 
and mortality. 
 
Procedures 
 
 The experiment was conducted in a 2,000-
sow commercial farm in Northeastern Kansas 
with a history of PCVD. A total of 1,470 
weaned pigs (825 barrows and 645 gilts) were 
ear-tagged for identification and randomly al-
lotted to one of three treatments with gilts and 
barrows equally allocated to each treatment 
group. Pigs were placed on test from three dif-
ferent weaning groups and weaning group was 
considered a block. All pigs were free of any 
physical defect and in good body condition. 
The treatments included a negative control 
(non-vaccinated), 1-dose-vaccinated, and 2-
dose vaccinated pigs. The 1-dose pigs were 
vaccinated one week after weaning while 2-
dose pigs were vaccinated at weaning and re-
peated three weeks later. The vaccines were 
commercially available (1-dose: Fort Dodge, 
2-dose: Intervet) and administered according 
to label instructions.  
 
Each weaning group was initially housed 
in three separate mechanically ventilated nurs-
ery rooms and were then transferred to open-
sided, naturally ventilated buildings during the 
growing to finishing phase. All on-test pigs 
were weighed on days 0, 113, and 143 and just 
prior to market to determine average daily 
gain. Weighing of pigs just prior to market 
was done in several batches for each group as 
part of the topping-out procedure of the farm. 
Thus, heavier pigs were weighed earlier than 
the rest of the pigs if they already weighed at 
least 270 lb before the scheduled weigh date 
for each block.  Average daily gain was ana-
lyzed from only those pigs that were mar-
keted. Only weight gains of pigs marketed 
were used for the calculation of ADG and 
weight gains of dead pigs were not used in the 
calculation for ADG.  
 
On-test pigs that died were recorded and 
mortality rate was calculated as number of 
deaths divided by the initial number of pigs 
placed on test. A total of 15 pigs (5 nursery 
and 10 finishing) with clinical signs indicative 
of PCVD were submitted to the KSU Diag-
nostic Laboratory for necropsy and histopa-
thological examination to confirm the pres-
ence of PCV2 infection.  
 
Data were analyzed as a 3 × 2 factorial 
randomized complete block design using the 
MIXED procedure of SAS. The fixed effects 
were vaccine treatment (control, 1-dose, and 
2-dose) and sex (barrow or gilt) with the ran-
dom effect of wean group. 
 
Results and Discussion 
 
 Histopathologic lesions associated with 
PCV2 infection were noted in pigs necropsied 
from each of the three weaning groups. Aver-
age weight of pigs given the 2-dose vaccine 
was greater (P<0.05) than the control pigs at 
mid-finishing (d 113 on-test) but not different 
from pigs that were given the 1-dose vaccine, 
which were intermediate. At day 143 on-test, 
no significant difference in average pig weight 
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was observed between the two vaccinated 
groups. However, the 1-dose vaccinated and 
2-dose vaccinated groups were heavier by 7.6 
and 10.2 lb (P<0.05), respectively, than the 
control groups. This is demonstrated by the 
greater number of pigs weighing 260 lb or 
more in the vaccinated groups compared to the 
control group at d 143 (Figure 1).  Pigs on the 
2-dose treatment had heavier (P<0.05) off-test 
weights than did non-vaccinated pigs, and 1-
dose treated pigs were intermediate. However, 
weight differences between the vaccinated 
groups and the control group was noticeably 
smaller at off-test compared to differences at d 
143. This may be explained by the fact that all 
groups were topped out several days before 
they were taken off test leaving the rest of the 
pigs within close weight range across all 
groups.  
 
Also, the control group was on test longer 
compared to the two groups, which allowed 
them to gain more weight and close the weight 
gap. There were no sex by treatment interac-
tions observed, but as expected, barrows were 
significantly heavier (P<0.05) than gilts on d 
113 up to market. 
 
 There was no significant difference in 
ADG among the pigs from the 1-dose and 2-
dose vaccinated groups from d 0 to 113, 143, 
or off-test. However, on all occasions both 
vaccinated groups exhibited greater ADG 
(P<0.05) compared to the control group. This 
explains the widening gap in average weights 
between the vaccinated groups and control 
group at d 113 and 143 on-test. All groups did 
not exhibit any significant difference in ADG 
from Day 113 to Day 143 and at off-test, 
which indicates that significant difference in 
growth rates occurs between d 0 and 113. 
 
 No differences in mortality rate were 
noted between any of the treatment groups. 
However, the two vaccinated groups had 3% 
lower mortality compared to the control group 
(7.7 and 7.8% vs. 11.0%, respectively). We 
believe that the absence of statistical differ-
ence among the treatments is due to the 
greater variability as a result of a respiratory 
disease outbreak during the trial. A clinical 
outbreak of bacterial disease due to Haemo-
philus parasuis was noted in two nursery 
groups. Additionally, an outbreak of respira-
tory disease due to Actinobacillus pleu-
ropneumoniae was noted in one finisher 
group. 
 
 In conclusion, both commercial PCV2 
vaccines were effective in improving the 
growth performance of pigs from weaning to 
finishing as shown by heavier weights and 
greater ADG of the vaccinated groups. There 
were no statistically significant differences 
between the two vaccines in terms of the pa-
rameters measured. However, pigs given the 
2-dose vaccine were 2.6 lb heavier than those 
given the 1-dose vaccine at d 143 after wean-
ing. 
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Table 1. Effects of PCV2 Vaccine on Growth Performance and Mortality Rate1
Vaccine Main Effect   Sex Main Effect   P-values 
Item Control 1-dose2 2-dose3  Barrows Gilts  Vaccine Sex 
Weight, lb          
   D 0 19.1 19.6 19.3  19.3 19.4  0.24 0.50 
   D 113 181.8a 188.2ab 190.7b  190.3 183.5  0.04 <0.0001
   D 143 237.3a 244.8b 247.4b  248.7 237.6  0.03 <0.0001
   Off-test 256.7 a 261.8 ab 265.0 b  265.3 257.1  0.05 <0.0001
          
Days On-test 153.2 151.8 151.9  151.2 153.3  0.08 <0.0001
          
ADG, lb          
   D 0 to 113 1.44a 1.49b 1.52b  1.51 1.45  0.02 <0.0001
   D 0 to 143 1.53a 1.58b 1.60b  1.61 1.53  0.02 <0.0001
   D 0 to Market 1.55a 1.60b 1.62b  1.63 1.55  0.02 <0.0001
   D 113 to D 143 1.89 1.91 1.94  2.00 1.84  0.39 <0.0001
   D113 to Market 1.89 1.93 1.95  2.00 1.84  0.25 <0.0001
          
Mortality, % 11.0 7.8 7.7  8.7 9.0  0.42 0.86 
a,,bMeans within the vaccine main effect lacking a common superscript differ P<0.05. 
1A total of 1,470 pigs were randomly assigned at weaning (d 0) to one of the three vaccine treatments 
within barrows and gilts.  
21-dose was the PCV2 vaccine available from Fort Dodge administered one week after weaning . 
32-dose was the commercially available vaccine from Intervet administered at weaning and 3 weeks 
later. 
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Figure 1. Comparative Weight Distribution of Treatment Groups at Day 143 on-Test. 
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